Anthony Harmar

List of Publications by Year
in descending order

86 papers	9,976 citations	61984 43 h-index	60623 81 g-index
86 all docs	86 docs citations	86 times ranked	9442 citing authors

#	Article	IF	Citations
1	Is systems pharmacology ready to impact upon therapy development? A study on the cholesterol biosynthesis pathway. British Journal of Pharmacology, 2017, 174, 4362-4382.	5.4	17
2	The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Research, 2014, 42, D1098-D1106.	14.5	826
3	The Concise Guide to PHARMACOLOGY 2013/14: G Proteinâ€Coupled Receptors. British Journal of Pharmacology, 2013, 170, 1459-1581.	5.4	528
4	International Union of Basic and Clinical Pharmacology. LXXXVIII. G Protein-Coupled Receptor List: Recommendations for New Pairings with Cognate Ligands. Pharmacological Reviews, 2013, 65, 967-986.	16.0	250
5	Evolving pharmacology of orphan <scp>GPCR</scp>s: IUPHAR Commentary. British Journal of Pharmacology, 2013, 170, 693-695.	5.4	8
6	IUPHAR-DB: updated database content and new features. Nucleic Acids Research, 2013, 41, D1083-D1088.	14.5	94
7	GuideToPharmacology.org â€" an update. British Journal of Pharmacology, 2012, 167, 697-698.	5.4	3
8	Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclaseâ€activating polypeptide: IUPHAR Review 1. British Journal of Pharmacology, 2012, 166, 4-17.	5.4	385
9	Calling all pharmacologists with time to spare! We need you! Build the drug discovery knowledge base, GuidetoPharmacology.org. British Journal of Pharmacology, 2012, 167, 1393-1394.	5.4	1
10	How to Use the IUPHAR Receptor Database to Navigate Pharmacological Data. Methods in Molecular Biology, 2012, 897, 15-29.	0.9	2
11	Activation of Thiazide-Sensitive Co-Transport by Angiotensin II in the cyp1a1-Ren2 Hypertensive Rat. PLoS ONE, 2012, 7, e36311.	2.5	24
12	New updated GRAC Fifth Edition with searchable online version Launch of new portal Guide to Pharmacology in association with NC-IUPHAR Transporter-Themed Issue. British Journal of Pharmacology, 2011, 164, 1749-1750.	5.4	10
13	IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data. Nucleic Acids Research, 2011, 39, D534-D538.	14.5	96
14	Circadian Control of Mouse Heart Rate and Blood Pressure by the Suprachiasmatic Nuclei: Behavioral Effects Are More Significant than Direct Outputs. PLoS ONE, 2010, 5, e9783.	2.5	66
15	Dietary Modulation of Drosophila Sleep-Wake Behaviour. PLoS ONE, 2010, 5, e12062.	2.5	72
16	IUPHAR-DB: An Expert-Curated, Peer-Reviewed Database of Receptors and Ion Channels. Nature Precedings, 2009, , .	0.1	0
17	IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Research, 2009, 37, D680-D685.	14.5	199
18	Sex influences the effect of a lifelong increase in serotonin transporter function on cerebral metabolism. Journal of Neuroscience Research, 2009, 87, 2375-2385.	2.9	11

#	Article	IF	Citations
19	The Neurotransmitter VIP Expands the Pool of Symmetrically Dividing Postnatal Dentate Gyrus Precursors via VPAC2Receptors or Directs Them Toward a Neuronal Fate via VPAC1receptors. Stem Cells, 2009, 27, 2539-2551.	3.2	37
20	Timed feeding of mice modulates lightâ€entrained circadian rhythms of reticulated platelet abundance and plasma thrombopoietin and affects gene expression in megakaryocytes. British Journal of Haematology, 2009, 146, 185-192.	2.5	17
21	Evidence that genetic variation in 5-HT transporter expression is linked to changes in 5-HT2A receptor function. Neuropharmacology, 2008, 54, 776-783.	4.1	41
22	Converging Evidence in Support of the Serotonin Hypothesis of Dexfenfluramine-Induced Pulmonary Hypertension With Novel Transgenic Mice. Circulation, 2008, 117, 2928-2937.	1.6	82
23	Entrainment to Feeding but Not to Light: Circadian Phenotype of VPAC₂Receptor-Null Mice. Journal of Neuroscience, 2007, 27, 4351-4358.	3.6	82
24	VIP receptors control excitability of suprachiasmatic nuclei neurones. Pflugers Archiv European Journal of Physiology, 2006, 452, 7-15.	2.8	43
25	Synchronization and Maintenance of Timekeeping in Suprachiasmatic Circadian Clock Cells by Neuropeptidergic Signaling. Current Biology, 2006, 16, 599-605.	3.9	397
26	Increased Expression of the 5-HT Transporter Confers a Low- Anxiety Phenotype Linked to Decreased 5-HT Transmission. Journal of Neuroscience, 2006, 26, 8955-8964.	3.6	142
27	Expression of the human PAC1 receptor leads to dose-dependent hydrocephalus-related abnormalities in mice. Journal of Clinical Investigation, 2006, 116, 1924-1934.	8.2	51
28	Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nature Neuroscience, 2005, 8, 476-483.	14.8	664
29	International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List. Pharmacological Reviews, 2005, 57, 279-288.	16.0	452
30	Interdependent Serotonin Transporter and Receptor Pathways Regulate S100A4/Mts1, a Gene Associated With Pulmonary Vascular Disease. Circulation Research, 2005, 97, 227-235.	4.5	147
31	International Union of Pharmacology. LVI. Ghrelin Receptor Nomenclature, Distribution, and Function. Pharmacological Reviews, 2005, 57, 541-546.	16.0	215
32	Functional Interactions between 5-Hydroxytryptamine Receptors and the Serotonin Transporter in Pulmonary Arteries. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 539-548.	2.5	82
33	Overexpression of the 5-Hydroxytryptamine Transporter Gene. Circulation, 2004, 109, 2150-2155.	1.6	192
34	Distribution of the VPAC2 Receptor in Peripheral Tissues of the Mouse. Endocrinology, 2004, 145, 1203-1210.	2.8	83
35	Transgenic approach reveals expression of the VPAC₂ receptor in phenotypically defined neurons in the mouse suprachiasmatic nucleus and in its efferent target sites. European Journal of Neuroscience, 2004, 19, 2201-2211.	2.6	54
36	Receptors for gut peptides. Best Practice and Research in Clinical Endocrinology and Metabolism, 2004, 18, 463-475.	4.7	12

#	Article	IF	Citations
37	A hVIPR transgene as a novel tool for the analysis of circadian function in the mouse suprachiasmatic nucleus. European Journal of Neuroscience, 2003, 17, 2502-2502.	2.6	6
38	The mouse VPAC2receptor confers suprachiasmatic nuclei cellular rhythmicity and responsiveness to vasoactive intestinal polypeptidein vitro. European Journal of Neuroscience, 2003, 17, 197-204.	2.6	129
39	The VPAC2 Receptor Is Essential for Circadian Function in the Mouse Suprachiasmatic Nuclei. Cell, 2002, 109, 497-508.	28.9	488
40	Family-B G-protein-coupled receptors. Genome Biology, 2001, 2, reviews3013.1.	9.6	270
41	Refined mapping of the human serotonin transporter (SLC6A4) gene within 17q11 adjacent to the CPD and NF1 genes. European Journal of Human Genetics, 2000, 8, 75-78.	2.8	18
42	Structure of the human VIPR2 gene for vasoactive intestinal peptide receptor type 2. FEBS Letters, 1999, 458, 197-203.	2.8	21
43	Presence of Multiple Functional Polyadenylation Signals and a Single Nucleotide Polymorphism in the 3â€² Untranslated Region of the Human Serotonin Transporter Gene. Journal of Neurochemistry, 1999, 72, 1384-1388.	3.9	88
44	Desensitization of the Human Vasoactive Intestinal Peptide Receptor (hVIP2/PACAP R): Evidence for Agonist-Induced Receptor Phosphorylation and Internalizationa. Annals of the New York Academy of Sciences, 1998, 865, 64-72.	3.8	22
45	Circadian changes in PACAP type 1 (PAC1) receptor mRNA in the rat suprachiasmatic and supraoptic nuclei. Brain Research, 1998, 813, 218-222.	2.2	59
46	Expression of PACAP, and PACAP type 1 (PAC1) receptor mRNA during development of the mouse embryo. Developmental Brain Research, 1998, 109, 245-253.	1.7	65
47	Altered Allelic Distributions of the Serotonin Transporter Gene in Migraine Without Aura and Migraine with Aura. Cephalalgia, 1998, 18, 23-26.	3.9	87
48	Circadian changes in the expression of vasoactive intestinal peptide 2 receptor mRNA in the rat suprachiasmatic nuclei. Molecular Brain Research, 1998, 54, 108-112.	2.3	55
49	Celsr1, a Neural-Specific Gene Encoding an Unusual Seven-Pass Transmembrane Receptor, Maps to Mouse Chromosome 15 and Human Chromosome 22qter. Genomics, 1997, 45, 97-104.	2.9	64
50	Association of Short Alleles of a VNTR of the Serotonin Transporter Gene with Anxiety Symptoms in Patients Presenting After Deliberate Self Harm. Neuropharmacology, 1997, 36, 439-443.	4.1	43
51	Association between the serotonin transporter gene and affective disorder: The evidence so far. Molecular Medicine, 1997, 3, 90-93.	4.4	20
52	Expression of pituitary adenylate cyclase activating polypeptide receptors in the early mouse embryo as assessed by reverse transcription polymerase chain reaction and in situ hybridisation. Neuroscience Letters, 1996, 216, 45-48.	2.1	31
53	Chromosomal Localization in Mouse and Human of the Vasoactive Intestinal Peptide Receptor Type 2 Gene: A Possible Contributor to the Holoprosencephaly 3 Phenotype. Genomics, 1996, 37, 345-353.	2.9	40
54	Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet, The, 1996, 347, 731-733.	13.7	495

#	Article	IF	Citations
55	Function and dysfunction in the nervous system. Trends in Neurosciences, 1996, 19, 449-450.	8.6	7
56	Control of a Novel Adenylyl Cyclase by Calcineurin. Biochemical and Biophysical Research Communications, 1995, 214, 1000-1008.	2.1	97
57	The distribution of vasoactive intestinal peptide2 receptor messenger RNA in the rat brain and pituitary gland as assessed by in situ hybridization. Neuroscience, 1995, 67, 409-418.	2.3	110
58	The expression of the calcitonin receptor gene in the brain and pituitary gland of the rat. Neuroscience Letters, 1994, 181, 31-34.	2.1	40
59	The sequence of 5â€² flanking DNA from the rat preprotachykinin gene; analysis of putative transcription factor binding sites. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1993, 1172, 361-363.	2.4	7
60	Molecular cloning and expression of a cDNA encoding a receptor for pituitary adenylate cyclase activating polypeptide (PACAP). FEBS Letters, 1993, 329, 99-105.	2.8	111
61	The VIP₂ receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Letters, 1993, 334, 3-8.	2.8	453
62	Distribution of neuropeptides in dorsal root ganglia of the rat; substance P, somatostatin and calcitonin gene-related peptide. Neuroscience Letters, 1993, 153, 5-8.	2.1	16
63	5â€²-Flanking Sequences from the Rat Preprotachykinin Gene Direct High-Level Expression of a Reporter Gene in Adult Rat Sensory Neurons Transfected in Culture by Microinjection. Molecular and Cellular Neurosciences, 1993, 4, 164-172.	2.2	28
64	3.3 kb of 5â€² flanking DNA from the rat preprotachykinin gene directs high level expression of a reporter gene in microinjected dorsal root ganglion neurons but not in transgenic mice. Regulatory Peptides, 1993, 46, 67-69.	1.9	11
65	Increased expression of preprotachykinin, calcitonin gene-related peptide, but not vasoactive intestinal peptide messenger RNA in dorsal root ganglia during the development of adjuvant monoarthritis in the rat. Molecular Brain Research, 1992, 16, 143-149.	2.3	174
66	Increase in substance P and CGRP, but not somatostatin content of innervating dorsal root ganglia in adjuvant monoarthritis in the rat. Neuroscience Letters, 1992, 137, 257-260.	2.1	115
67	A single-stranded DNA binding protein which interacts with sequences within the bovine preprotachykinin promoter: Regulation by nerve growth factor. Biochemical and Biophysical Research Communications, 1992, 187, 1395-1400.	2.1	9
68	Identification of Nerve Growth Factor-Responsive Sequences Within the 5â€² Region of the Bovine Preprotachykinin Gene. DNA and Cell Biology, 1991, 10, 743-749.	1.9	24
69	Effect of adrenalectomy and dexamethasone on neuropeptide content of dorsal root ganglia in the rat. Brain Research, 1991, 564, 27-30.	2.2	76
70	Localization of beta pre-protachykinin mRNA in nodose ganglion. Neuropeptides, 1991, 20, 145-150.	2.2	5
71	The effect of nerve growth factor on afferent neurons. European Journal of Pharmacology, 1990, 183, 2037-2038.	3.5	0
72	Identification and cDNA sequence of Î´-preprotachykinin, a fourth splicing variant of the rat substance P precursor. FEBS Letters, 1990, 275, 22-24.	2.8	82

#	Article	IF	Citations
73	Nerve growth factor regulates expression of neuropeptide genes in adult sensory neurons. Nature, 1989, 337, 362-364.	27.8	915
74	An antiserum to the extracellular domain of the Alzheimer amyloid precursor recognizes 70 and 88 kDa brain proteins. FEBS Letters, 1989, 257, 238-240.	2.8	3
75	An antiserum to the C-terminus of the Alzheimer amyloid precursor recognizes a soluble 70 kDa protein. FEBS Letters, 1988, 237, 196-198.	2.8	5
76	The Role of RNA Splicing and Post-Translational Proteolytic Processing in the Biosynthesis of Neuropeptides. , 1988, , 29-33.		0
77	cDNA sequence of human Î²-preprotachykinin, the common precursor to substance P and neurokinin A. FEBS Letters, 1986, 208, 67-72.	2.8	97
78	[23] Methods for the identification of neuropeptide processing products: Somatostatin and the tachykinins. Methods in Enzymology, 1986, 124, 335-348.	1.0	18
79	Biosynthesis of the Tachykinins and Somatostatin. , 1986, , 147-158.		0
80	Peptides and Amines in Alzheimer-Type Dementia and Downï¿½s Syndrome. Interdisciplinary Topics in Gerontology and Geriatrics, 1985, 19, 175-183.	2.6	0
81	Different patterns of molecular forms of somatostatin are released by the rat median eminence and hypothalamus. Neuroscience Letters, 1985, 57, 215-220.	2.1	15
82	Rat sensory ganglia incorporate radiolabelled amino acids into substance K (neurokinin Î±) in vitro. Neuroscience Letters, 1984, 51, 387-391.	2.1	22
83	Characterization and partial purification of a 5,700 dalton form of substance P-like immunoreactivity from the rat hypothalamus. Brain Research, 1984, 323, 342-344.	2.2	17
84	Local changes in cerebral 2-deoxyglucose uptake during alphaxalone anaesthesia with special reference to the Habenulo-Interpeduncular system. Brain Research, 1984, 300, 19-26.	2.2	24
85	Thyrotropin-releasing hormone, luteinizing hormone-releasing hormone and substance P immuno-reactivity in post-mortem brain from cases of alzheimer-type dementia and Down's syndrome. Brain Research, 1983, 258, 45-52.	2.2	66
86	Intranigral injection of capsaicin enhances motor activity and depletes nigral 5-hydroxytryptamine but not substance P. Neuropharmacology, 1981, 20, 341-346.	4.1	43